ECE2023 Eposter Presentations Pituitary and Neuroendocrinology (234 abstracts)
Growth hormone treatment tends to promote hepatic VLDL1-triglyceride export in humans
Clemens Baumgartner 1 , Matthaeus Metz 1 , Franziska Schnait 1 , Anna Tosin 1 , Marianna Beghini 1 , Paul Fellinger 1 , Hannes Beiglboeck 1 , Lorenz Pfleger 1 , Greisa Vila 1 , Anton Luger 1 , Alexandra Kautzky-Willer 1 , Herbert Stangl 2 , Martin Krssak 1,3 , Clemens Fürnsinn 1 , Thomas Scherer 1 , Michael Krebs 1 & Peter Wolf 1
1Medical University of Vienna, Internal Medicine III, Division of Endocrinology and Metabolism, Vienna, Austria; 2Medical University of Vienna, Institute of Medical Chemistry, Center for Pathobiochemistry and Genetics, Vienna, Austria; 3Medical University of Vienna, High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Vienna, Austria
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a systemic, metabolic condition associated with increased morbidity and mortality. Defined by an increase in hepatic lipid content (HCL), NAFLD develops in consequence of lipid oversupply and/or a diminished disposal of hepatic lipids. The latter may include an impaired export of triglycerides (TG) via the secretion of very-low density lipoprotein1 (VLDL1) particles, an important mechanism of the liver to protect itself from steatosis. Growth hormone (GH) is known for its beneficial effects on body composition and increases lean body mass by favouring overall lipid consumption. Furthermore, studies in acromegalic patients suggest excessive GH secretion to decrease HCL. Although current data are conflicting, GH might mediate the reduction of HCL by fostering the export of TG rich VLDL1 particles.
Aim and methods: We aimed to determine the impact of exogenous GH treatment on hepatic TG export, hypothesizing an increase of VLDL1-TG secretion after short-term GH excess. Therefore, using an intralipid infusion protocol, VLDL1-TG secretion was assessed in five healthy, male volunteers (age 26.8±4.7 years; BMI 23.8±3.8 kg/m2) at baseline and after one week of GH treatment with daily injections of 2 mg Genotropin®. Parameters are given as mean ±standard deviation and paired t-test was used for analysis.
Results: After one week of GH treatment, secretion of VLDL1-TG increased in four of five cases, depicted by a mean increase of 10.5% (687.8±289.2 vs. 813.2±518.8 mg/h, P=0.294). Marked increases in serum IGF-1 (231.2±22.3 vs. 480.4±101.8 ng/ml, P=0.009), insulin (8.3±3.1 vs. 16±3.6 μIU/ml, P=0.021), and C-peptide (1.8±0.3 vs. 2.5±0.7 ng/ml, P=0.088) indicated a sufficient impact of GH dosage.
Future perspective: This preliminary analysis shows a trend towards increased VLDL1-TG secretion in response to short-term subcutaneous GH treatment in humans. Further investigation of GH-mediated hepatic TG export might pave the way for novel therapeutic strategies in the treatment of NAFLD.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more